AffPaysInc.i
Curation
Accueil
Racine
Curation
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration Tocilizumab - Curation (Accueil)

Index « AffPaysInc.i » - entrée « Nagoya »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Nagasaki University Graduate School of Biomedical Sciences < Nagoya < Nagoya Japan  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
002A27 (2013) T. Kojima ; K. Funahashi ; N. Takahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Yabe [Japon] ; N. IshiguroTHU0124 Importance of monitoring of C-reactive protein level to predict achievement of better clinical outcome during treatment with tocilizumab in patients with rheumatoid arthritis
002A43 (2013) H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon]THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan
002B40 (2013) Y. Kanayama ; T. Kojima ; Y. Hirano [Japon] ; N. Takahashi ; K. Funahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Oishi [Japon] ; N. IshiguroSAT0155 Radiographic progression of cervical lesions and hands in patients with rheumatoid arthritis receiving infliximab treatment from japanese tbc registry; two years of follow-up
002B48 (2013) Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. IshiguroSAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification
002B65 (2013) M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon]SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan
002B86 (2013) H. Ishikawa ; Y. Hirano ; A. Kaneko ; D. Kida ; T. Sato ; T. Kojima ; T. Kanamono [Japon] ; N. IshiguroSAT0093 Pregnancy in patients with rheumatoid arthritis treated witn biological agents: Results of the 8-year of japanese tbc registry
003067 (2013) Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. IshiguroAB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry
003092 (2013) N. Asai ; T. Kobayakawa ; K. Saito ; T. Shioura ; Y. Yabe [Japon] ; T. Kojima ; A. Kaneko [Japon] ; N. IshiguroAB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry
003143 (2013) A. Kaneko ; N. Takahashi ; D. Kida ; Y. Hirano [Japon] ; H. Ishikawa ; T. Kojima ; N. IshiguroAB0515 Predictors of clinical remission (DAS28CRP<2.6) in patients with RA who were treated with abatacept
003185 (2013) Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. IshiguroAB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration
003187 (2013) Y. Kanayama ; T. Kojima ; Y. Hirano ; Y. Yabe [Japon] ; N. Takahashi ; K. Funahashi ; Y. Oishi ; N. IshiguroAB0336 Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving tocilizumab treatment comparison with infliximab treatment from japanese tbcr
003239 (2013) Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/AffPaysInc.i -k "Nagoya" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/AffPaysInc.i  \
                -Sk "Nagoya" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Curation
   |type=    indexItem
   |index=    AffPaysInc.i
   |clé=    Nagoya
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021